Jubilant Pharmova Limited announced strong financial performance for FY26, with total revenue growing 14% to Rs. 8,346 Cr., driven by solid expansion across all business segments. The company’s annual EBITDA grew by 8% to Rs. 1,326 Cr., while Normalised PAT reached Rs. 442 Cr., a 7% year-on-year increase. Despite temporary production challenges at the Montreal facility, the company remains firmly on track with its long-term Vision 2030 growth strategy.
Annual Financial Performance
For the financial year ended March 31, 2026, Jubilant Pharmova achieved solid growth with revenue reaching Rs. 8,280 Cr., reflecting a 14% increase on a year-on-year basis. This performance was supported by robust growth in the CDMO Sterile Injectables business. The company reported an annual EBITDA of Rs. 1,326 Cr., up 8% compared to the previous year, despite impact from lower production at the CMO Montreal facility during the year.
Segmental Business Growth
The company demonstrated strong momentum across its key business units:
- CDMO Sterile Injectables: Experienced 38% revenue growth to Rs. 1,755 Cr., largely driven by the successful launch and scale-up of Line 3 at the Spokane facility.
- Radiopharmaceuticals: Revenue grew by 10% to Rs. 1,178 Cr., supported by strong performance in the Ruby-Fill® portfolio.
- Allergy Immunotherapy: Achieved a 12% revenue increase to Rs. 785 Cr., maintaining strong margins of 35%.
- Generics: Reported a significant turnaround with revenue growth of 13% to Rs. 774 Cr. and EBITDA growth of 250% to Rs. 83 Cr.
Strategic Outlook and Vision 2030
Jubilant Pharmova continues to advance its Vision 2030, aiming to double its revenues by FY30. Key growth drivers include the ongoing expansion of the PET manufacturing network from three to nine sites, expected to be fully operational by FY28. Furthermore, the company is making significant strides in its Proprietary Novel Drugs pipeline, with JBI-802 and JBI-778 clinical trials actively enrolling patients. Management anticipates EBITDA margins will strengthen from H2’FY27 onwards as production stabilizes at the Montreal facility and new capacity projects reach full utilization.
Source: BSE
